Berkshire Asset Management LLC PA lifted its position in Pfizer, Inc. (NYSE:PFE) by 0.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 562,516 shares of the biopharmaceutical company’s stock after purchasing an additional 5,203 shares during the quarter. Pfizer accounts for 2.1% of Berkshire Asset Management LLC PA’s portfolio, making the stock its 13th largest position. Berkshire Asset Management LLC PA’s holdings in Pfizer were worth $18,895,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Eagle Capital Management LLC acquired a new position in Pfizer during the first quarter worth $2,919,000. Cable Hill Partners LLC raised its stake in Pfizer by 6.0% during the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 265 shares in the last quarter. Berson & Corrado Investment Advisors LLC raised its stake in Pfizer by 1.8% during the first quarter. Berson & Corrado Investment Advisors LLC now owns 38,387 shares of the biopharmaceutical company’s stock worth $1,313,000 after acquiring an additional 680 shares in the last quarter. First National Bank of Mount Dora Trust Investment Services raised its stake in Pfizer by 90.9% during the first quarter. First National Bank of Mount Dora Trust Investment Services now owns 94,415 shares of the biopharmaceutical company’s stock worth $3,230,000 after acquiring an additional 44,945 shares in the last quarter. Finally, Forte Capital LLC ADV raised its stake in Pfizer by 16.5% during the first quarter. Forte Capital LLC ADV now owns 9,929 shares of the biopharmaceutical company’s stock worth $340,000 after acquiring an additional 1,406 shares in the last quarter. Institutional investors and hedge funds own 69.00% of the company’s stock.

Pfizer, Inc. (PFE) traded down 0.183% during trading on Tuesday, reaching $35.485. The company had a trading volume of 6,188,163 shares. The firm’s 50 day moving average price is $33.71 and its 200 day moving average price is $33.53. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.84. The firm has a market capitalization of $211.04 billion, a PE ratio of 25.958 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. Analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Friday, August 4th were issued a $0.32 dividend. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.60%. Pfizer’s payout ratio is presently 94.12%.

Several research analysts have issued reports on the company. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective for the company. in a research note on Wednesday, September 13th. Jefferies Group LLC set a $37.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Monday. BMO Capital Markets reiterated a “buy” rating and set a $37.00 price objective on shares of Pfizer in a research note on Thursday, September 14th. Finally, BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $37.83.

ILLEGAL ACTIVITY WARNING: “Berkshire Asset Management LLC PA Purchases 5,203 Shares of Pfizer, Inc. (PFE)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/19/berkshire-asset-management-llc-pa-purchases-5203-shares-of-pfizer-inc-pfe.html.

In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last ninety days, insiders sold 464,521 shares of company stock valued at $15,813,961. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.